DK1027047T3 - Eprosartan-arginyl-ladningsneutraliseringskompleks og fremgangsmåde til dets fremstilling og formulering - Google Patents

Eprosartan-arginyl-ladningsneutraliseringskompleks og fremgangsmåde til dets fremstilling og formulering

Info

Publication number
DK1027047T3
DK1027047T3 DK98939213T DK98939213T DK1027047T3 DK 1027047 T3 DK1027047 T3 DK 1027047T3 DK 98939213 T DK98939213 T DK 98939213T DK 98939213 T DK98939213 T DK 98939213T DK 1027047 T3 DK1027047 T3 DK 1027047T3
Authority
DK
Denmark
Prior art keywords
eprosartan
formulation
preparation
charge neutralization
arginyl charge
Prior art date
Application number
DK98939213T
Other languages
Danish (da)
English (en)
Inventor
Gopadi M Venkatesh
Manga R Gudipati
John M Jushchyshyn
Nageswara R Palepu
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK1027047T3 publication Critical patent/DK1027047T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DK98939213T 1997-08-06 1998-08-04 Eprosartan-arginyl-ladningsneutraliseringskompleks og fremgangsmåde til dets fremstilling og formulering DK1027047T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5499097P 1997-08-06 1997-08-06
PCT/US1998/016245 WO1999007365A1 (en) 1997-08-06 1998-08-04 Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation

Publications (1)

Publication Number Publication Date
DK1027047T3 true DK1027047T3 (da) 2007-01-29

Family

ID=21994861

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98939213T DK1027047T3 (da) 1997-08-06 1998-08-04 Eprosartan-arginyl-ladningsneutraliseringskompleks og fremgangsmåde til dets fremstilling og formulering

Country Status (27)

Country Link
EP (1) EP1027047B1 (no)
JP (1) JP4463975B2 (no)
KR (1) KR100508044B1 (no)
CN (1) CN1276724A (no)
AR (1) AR015930A1 (no)
AT (1) ATE341325T1 (no)
AU (1) AU739295B2 (no)
BR (1) BR9811926A (no)
CA (1) CA2299470C (no)
CO (1) CO4960666A1 (no)
CY (1) CY1105851T1 (no)
CZ (1) CZ296274B6 (no)
DE (1) DE69836095T2 (no)
DK (1) DK1027047T3 (no)
ES (1) ES2273433T3 (no)
HK (1) HK1031688A1 (no)
HU (1) HUP0201624A3 (no)
IL (1) IL134378A (no)
NO (1) NO317771B1 (no)
NZ (1) NZ502644A (no)
PL (1) PL198875B1 (no)
PT (1) PT1027047E (no)
SA (1) SA98190592B1 (no)
TR (1) TR200000350T2 (no)
TW (1) TW570921B (no)
WO (1) WO1999007365A1 (no)
ZA (1) ZA987018B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
WO2000066161A1 (fr) * 1999-04-28 2000-11-09 Takeda Chemical Industries, Ltd. Preventifs / remedes / inhibiteurs de progression pour retinopathie simplex ou retinopathie preproliferante
JP3874419B2 (ja) 2003-01-31 2007-01-31 三共株式会社 動脈硬化及び高血圧症の予防及び治療のための医薬
NO323391B1 (no) 2005-09-28 2007-04-23 Hts Hans Torgersen & Sonn As Barnepose
US20100278909A1 (en) * 2007-06-06 2010-11-04 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
JP5476782B2 (ja) * 2009-04-21 2014-04-23 大正製薬株式会社 アルギニン含有錠剤の製造方法
JP5446716B2 (ja) * 2009-10-21 2014-03-19 大正製薬株式会社 アルギニン及びカルニチン含有錠剤の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
AU656551B2 (en) * 1990-12-14 1995-02-09 Smithkline Beecham Corporation Angiotensin II receptor blocking compositions
EP0563238B1 (en) * 1990-12-14 2002-05-22 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
DE4208052A1 (de) * 1992-03-13 1993-09-16 Bayer Ag Imidazolyl substituierte phenylessigsaeureamide
FR2688781B1 (fr) * 1992-03-23 1994-07-01 Sanofi Elf Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
DE4210787A1 (de) * 1992-04-01 1993-10-07 Bayer Ag Cycloalkyl- und Heterocyclyl substituierte Imidazolylpropensäurederivate
JPH0841053A (ja) * 1994-07-28 1996-02-13 Nkk Corp ヘテロアリールアルキル基を有するピリミジン誘導体及 び該誘導体を有効成分として含有するアンジオテンシン ｉｉ拮抗剤
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
WO1997021707A1 (en) * 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone

Also Published As

Publication number Publication date
NO317771B1 (no) 2004-12-13
ATE341325T1 (de) 2006-10-15
ZA987018B (en) 1999-02-08
CA2299470C (en) 2010-01-26
KR100508044B1 (ko) 2005-08-17
JP4463975B2 (ja) 2010-05-19
IL134378A0 (en) 2001-04-30
JP2001513498A (ja) 2001-09-04
CZ2000406A3 (cs) 2000-09-13
NO20000577L (no) 2000-02-29
AR015930A1 (es) 2001-05-30
AU8768898A (en) 1999-03-01
DE69836095T2 (de) 2007-04-12
EP1027047A4 (en) 2002-09-18
ES2273433T3 (es) 2007-05-01
IL134378A (en) 2004-02-19
CA2299470A1 (en) 1999-02-18
HK1031688A1 (en) 2001-06-22
CN1276724A (zh) 2000-12-13
DE69836095D1 (de) 2006-11-16
KR20010022582A (ko) 2001-03-26
SA98190592B1 (ar) 2006-06-20
NZ502644A (en) 2002-03-01
BR9811926A (pt) 2000-08-22
PL341562A1 (en) 2001-04-23
CO4960666A1 (es) 2000-09-25
PL198875B1 (pl) 2008-07-31
TW570921B (en) 2004-01-11
CZ296274B6 (cs) 2006-02-15
NO20000577D0 (no) 2000-02-04
TR200000350T2 (tr) 2000-12-21
CY1105851T1 (el) 2011-02-02
AU739295B2 (en) 2001-10-11
PT1027047E (pt) 2007-01-31
WO1999007365A1 (en) 1999-02-18
EP1027047B1 (en) 2006-10-04
EP1027047A1 (en) 2000-08-16
HUP0201624A2 (hu) 2002-12-28
HUP0201624A3 (en) 2003-03-28

Similar Documents

Publication Publication Date Title
DK0739898T3 (da) Phosphononmoneosternukleinsyrer, fremgangsmåde til fremstilling deraf og anvendelse deraf
HK1029914A1 (en) Device and pharmaceutical agent for treatment of dysmenorrhea
DE69634256D1 (de) Zementformulierung
DE69800854D1 (de) Haarbehandlungsmittel
ID24654A (id) Formulasi farmasi omeprazola
EE03380B1 (et) Farmatseutiline aerosoolpreparaat ja selle valmistamismeetod
IL123986A0 (en) Antithombotic agents process for their preparation and pharmaceutical compositions comprising them
GB9407386D0 (en) Pharmaceutical formulation
GB9402203D0 (en) Pharmaceutical formulation
DE69817706D1 (de) UV-Schutzformulierung
NO20000602D0 (no) Krembasert matsammensetning og fremgangsmÕte for fremstilling derav
IL112521A0 (en) Pharmaceutical formulation
ID22755A (id) Proses prapengolahan kosmetik bekas
DK0889880T3 (da) Eprosartan-dihydrat og fremgangsmåde til fremstilling deraf samt formulering
BR9610396A (pt) Formulação farmacêutica
DK0991666T3 (da) Alfa-1-antitrypsin-præparat og fremgangsmåde til fremstilling heraf
NO20002202D0 (no) Støpte polyolefin- og polyfenyloksidprodukter og fremgangsmÕte til fremstilling derav
HUP0001486A3 (en) Pharmaceutical composition for topical use cantaining nimesulide gel systems and process for preparation thereof
GB9405856D0 (en) Pharmaceutical formulation
GB9416599D0 (en) Pharmaceutical formulation
DK1027047T3 (da) Eprosartan-arginyl-ladningsneutraliseringskompleks og fremgangsmåde til dets fremstilling og formulering
PT939083E (pt) Complexos de ferro-succinilcaseina procedimento para sua preparacao e suas composicoes farmaceuticas
DK1005342T3 (da) Farmaceutiske sammensætninger indeholdende tizoxanid og nitazoxanid
GB9709739D0 (en) Pharmaceutical formulation
EP0987942A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD OF USE